The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

Arcutis Biotherapeutics, Inc.331 enrolled

Overview

This is a parallel group, double blind, vehicle-controlled study in which roflumilast (ARQ-151) cream 0.3%, roflumilast cream 0.15%, or vehicle cream is applied once daily (QD) for 84 days to subjects with chronic plaque psoriasis involving between 2 and 20% body surface area.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

331

Conditions

Plaque Psoriasis

Interventions

Roflumilast Cream 0.3%DRUG

Applied once daily for 12 weeks

Roflumilast Cream 0.15%DRUG

Applied once daily for 12 weeks

Vehicle CreamDRUG

Applied once daily for 12 weeks

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants legally competent to sign and give informed consent * Males and females ages 18 years and older (inclusive) * Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined by the Investigator * Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception throughout the trial. * In good health as judged by the Investigator, based on medical history, physical examination, serum chemistry labs, hematology values, and urinalysis. * Subjects are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator. Exclusion Criteria: * Planned excessive exposure of treated area(s) to either natural or artificial sunlight or tanning bed. * Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding. * Previous treatment with roflumilast cream or its active ingredient * Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator. * Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of study medication. * Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.

Locations (30)

Outcomes

Primary Outcomes

Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' at Week 6

The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') at Week 6 is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity.

Time frame: Week 6

Secondary Outcomes

Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear'

The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity.

Time frame: Weeks 4, 8, and 12

Change From Baseline in Modified Psoriasis Area Severity Index (mPASI) Score

The percent change from baseline in mPASI score is presented. The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity. For scoring, the body is divided into four sections (head \[h\]: 10% of a person's skin; arms \[a\] 20%; trunk \[t\] 30%; legs (l\] 40%); for each section, the percent of area involved is estimated from 0 (0% involved) to 6 (90 to 100% involved). Then, within each area, the severity is estimated by three clinical signs: erythema ('E'; redness), induration ('T'; thickness), and desquamation ('S'; scaling). Severity parameters are measured on a scale of 0 to 4, from none to maximum severity possible. Each of these areas is scored by itself, and then the four scores are combined into the final mPASI, using the formula mPASI = 0.1 (Eh + Th + Sh) Ah + 0.2 (Ea + Ta + Sa) Aa + 0.3 (Et + Tt + St) At + 0.4 (El + Tl + Sl) Al.

Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

Percent Change From Baseline in Body Surface Area (BSA) Affected

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Arcutis Clinical Site 35

Beverly Hills, California, United States

Arcutis Clinical Site 29

Northridge, California, United States

Arcutis Clinical Site 28

San Diego, California, United States

Arcutis Clinical Site 27

Santa Monica, California, United States

Arcutis Clinical Site 12

Miami, Florida, United States

Arcutis Clinical Site 16

Sanford, Florida, United States

Arcutis Clinical Site 21

Louisville, Kentucky, United States

Arcutis Clinical Site 34

Clinton Township, Michigan, United States

Arcutis Clinical Site 33

Detroit, Michigan, United States

Arcutis Clinical Site 20

Fridley, Minnesota, United States

...and 20 more locations

The BSA affected by psoriasis was determined by the subject's hand method, where the subject's hand (including fingers) surface area was assumed to equal 1% of BSA. The mean percent change from baseline in BSA is presented.

Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' Plus a 2-Grade Improvement From Baseline

The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') plus a 2-grade improvement from baseline is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity.

Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

Percentage of Participants With an Intertriginous Area Investigator Global Assessment (I-IGA) Score of 'Clear' or 'Almost Clear' Who Had at Least Mild Lesions at Baseline

The percentage of participants (who had intertriginous area involvement with an I-IGA score of at least mild at baseline) with at least a 2-grade improvement in I-IGA score at Weeks 4, 6, 8, and 12 is presented.

Time frame: Weeks 4, 6, 8, and 12

Change From Baseline in Worst Itch-Numeric Rating Scale (WI-NRS) Pruritus Score

The WI-NRS is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. The mean (SD) change in WI-NRS score from baseline is presented.

Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

Percentage of Participants With Baseline Worst Itch-Numeric Rating Scale (WI-NRS) Pruritus Score ≥6 Who Experienced a 4-point Reduction

The percentage of participants who had baseline WI-NRS scores ≥6 who achieved a 4-point reduction in WI-NRS score at Weeks 4, 6, 8, and 12 is reported. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours.

Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

Percentage of Participants Achieving a Modified Psoriasis Area Severity Index-75 (mPASI-75) Compared to Baseline

The percentage of subjects achieving a 75% reduction in mPASI (eg, mPASI-75) score relative to baseline is presented. The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity.

Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

Percentage of Participants Achieving a Modified Psoriasis Area Severity Index-90 (mPASI-90) Compared to Baseline

The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity. The percentage of subjects achieving a 90% reduction in mPASI (eg, mPASI-90) score relative to baseline is presented.

Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

Change From Baseline in Psoriasis Symptom Diary (PSD) Total Score

The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 11 ("worst imaginable symptoms"). Scores range from 0 to 176, with higher scores indicating greater symptom severity. The mean (SD) change in PSD total score relative to baseline is presented for each treatment arm.

Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

Change From Baseline in Itch-Related Sleep Loss Numeric Rating Scale (NRS) Score

The Itch-Related Sleep Loss NRS is a single item scale scored from 0 ("no itch-related sleep loss") to 10 ("itch-related sleep loss as bad as it could be") assessing the severity of itch-related sleep loss in the past 24 hours. The mean (SD) change from the baseline NRS score is presented for each treatment arm.

Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

Change From Baseline in Dermatology Life Quality Index (DLQI) Score

The DLQI is a 10-item scale asking subject to rate the severity of symptoms during the past week. Each item is scored from 0 ("not at all" or "not relevant") to 3 or 4 ("very much") \[2 questions are scored 0 to 3 and 8 questions are scored 0 to 4\]. The total DLQI score ranges from 0 to 48, with higher scores indicating greater symptom severity. The mean (SD) change from baseline DLQI score is presented.

Time frame: Baseline (Day 1) and Weeks 4, 6, 8, and 12

Responses to Individual Questions of the Psoriasis Symptom Diary (PSD)

Two items from the PSD asking participants to rate the overall severity of psoriasis-related itching and pain during the past 24 hours are presented. Each item is scored on an 11-point scale ranging from 0 ("no symptom") to 10 ("worst imaginable symptom"), with lower scores indicating lower symptoms severity. The mean (SD) score is presented for each treatment arm.

Time frame: Weeks 4, 6, 8, and 12